Science | Nature | Cell | View More
Natural Products
Visnagin
Visnagin
ChemFaces products have been cited in many studies from excellent and top scientific journals
Product Name Visnagin
Price: $40 / 20mg
CAS No.: 82-57-5
Catalog No.: CFN97314
Molecular Formula: C13H10O4
Molecular Weight: 230.2 g/mol
Purity: >=98%
Type of Compound: Flavonoids
Physical Desc.: Yellow powder
Source: The herbs of Ammi visnaga.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Download: COA    MSDS    SDF    Manual
Similar structural: Comparison (Web)  (SDF)
Guestbook:
Contact Us
Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC
How to Order
Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com
Delivery time
Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal
Citing Use of our Products
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
Size /Price /Stock 10 mM * 1 mL in DMSO / $11.8 / In-stock
Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
Our products had been exported to the following research institutions and universities, And still growing.
  • Cornell University (USA)
  • Wroclaw Medical University (Poland)
  • Cancer Research Initatives Foun... (Malaysia)
  • Calcutta University (India)
  • University of Perugia (Italy)
  • Universidad Veracuzana (Mexico)
  • Univerzita Karlova v Praze (Czech Republic)
  • Vin?a Institute of Nuclear Scie... (Serbia)
  • Medizinische Universit?t Wien (Austria)
  • Universidad Industrial de Santa... (Colombia)
  • Biotech R&D Institute (USA)
  • More...
Package
Featured Products
(+)-Borneol

Catalog No: CFN70111
CAS No: 464-43-7
Price: $30/20mg
Dihydroevocarpine

Catalog No: CFN92786
CAS No: 15266-35-0
Price: $268/10mg
Notopterol

Catalog No: CFN98563
CAS No: 88206-46-6
Price: $80/20mg
Linarin

Catalog No: CFN98738
CAS No: 480-36-4
Price: $40/20mg
Isorhynchophylline

Catalog No: CFN96197
CAS No: 6859-01-4
Price: $138/20mg
3,4-Dihydroxybenzoic acid

Catalog No: CFN97568
CAS No: 99-50-3
Price: $30/20mg
Asimilobine

Catalog No: CFN96772
CAS No: 6871-21-2
Price: $ / mg
Dihydrophaseic acid

Catalog No: CFN98657
CAS No: 41756-77-8
Price: $ /
1,2,3,6-Tetragalloylglucose

Catalog No: CFN00447
CAS No: 79886-50-3
Price: $238/10mg
Alizarin

Catalog No: CFN92568
CAS No: 72-48-0
Price: $30/20mg
Related Screening Libraries
Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries
Biological Activity
Description: Visnagin has acute hypotensive, anti-inflammatory, and neuroprotective effects, it protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Visnagin can relax aortae previously contracted by noradrenaline, and weakly inhibit the hydrolytic activity of the cyclic nucleotide phosphodiesterase (PDE) isozymes (PDE5, PDE4, PDE3, cyclic GMP activated PDE2 and PDE1).
Targets: IL Receptor | TNF-α | COX | P450 (e.g. CYP17) | NOS | AP-1 | NF-kB | IFN-γ | PDE
In vitro:
PLoS One. 2013 Sep 19;8(9):e74917.
Khellin and visnagin differentially modulate AHR signaling and downstream CYP1A activity in human liver cells.[Pubmed: 24069365]
Khellin and Visnagin are two furanochromones that can be frequently found in ethnomedical formulations in Asia and the Middle East. Both compounds possess anti-inflammatory and analgesic properties, therefore modern medicine uses these compounds or structurally related derivatives for treatment of vitiligo, bronchial asthma and renal colics. Despite their frequent usage, the potential toxic properties of Visnagin and khellin are not well characterized up-to-now.
METHODS AND RESULTS:
The observed induction of several other members of the AHR gene battery, whose gene products are involved in regulation of cell growth, differentiation and migration, indicates that a further toxicological characterization of Visnagin and khelllin is urgently required in order to minimize potential drug-drug interactions and other toxic side-effects that may occur during therapeutic usage of these furanochromones.
In vivo:
Korean J Physiol Pharmacol. 2010 Oct;14(5):257-63.
Neuroprotective Effect of Visnagin on Kainic Acid-induced Neuronal Cell Death in the Mice Hippocampus.[Pubmed: 21165322 ]
Visnagin (4-methoxy-7-methyl-5H-furo[3,2-g][1]-benzopyran-5-one), which is an active principle extracted from the fruits of Ammi visnaga, has been used as a treatment for low blood-pressure and blocked blood vessel contraction by inhibition of calcium influx into blood cells. However, the neuroprotective effect of Visnagin was not clearly known until now.
METHODS AND RESULTS:
Thus, we investigated whether Visnagin has a neuroprotective effect against kainic acid (KA)-induced neuronal cell death. In the cresyl violet staining, pre-treatment or post-treatment Visnagin (100 mg/kg, p.o. or i.p.) showed a neuroprotective effect on KA (0.1 μg) toxicity. KA-induced gliosis and proinflammatory marker (IL-1β, TNF-α, IL-6, and COX-2) inductions were also suppressed by Visnagin administration.
CONCLUSIONS:
These results suggest that Visnagin has a neuroprotective effect in terms of suppressing KA-induced pathogenesis in the brain, and that these neuroprotective effects are associated with its anti-inflammatory effects.
Planta Med. 2000 Feb;66(1):35-9.
Cardiovascular effects of visnagin on rats.[Pubmed: 10705731]
The present article describes the effects of Visnagin on systolic blood pressure and heart rate in the anaesthetized rat.
METHODS AND RESULTS:
Intravenous administration of Visnagin (0.3-5 mg kg-1) produced dose-related decreases in blood pressure with no significative changes in heart rate. Under nitric oxide synthase inhibition (L-NAME, 50 mg kg-1) the hypotensive effects of Visnagin (5 mg kg-1) were not affected. Visnagin (5 x 10(-6) M-10(-4) M) produced a weak decrease in the rate and amplitude of spontaneous contractions in right atria. Visnagin also caused a weak decrease in peak contractile force and the df/dtmax with no significant changes in the time to peak tension or the time for total contraction in left atria driven at a basal rate of 1 Hz. Visnagin (10(-5) M, 5 x 10(-5) M and 10(-4) M) concentration-dependently decreased pressor response to KCl (IC50 = 5.1 +/- 2.5 x 10(-5) M) and noradrenaline (IC50 = 2.6 +/- 0.9 x 10(-5) M) in rat isolated mesenteric beds. Visnagin (3 x 10(-7) M-10(-4) M) induced a concentration-dependent relaxation of isolated mesenteric arteries contracted by noradrenaline (IC50 = 1.7 +/- 0.8 x 10(-5) M). The relaxant effects in the absence of functional endothelium were not significantly different (IC50 = 1.5 +/- 0.3 x 10(-5) M, P > 0.05) from those observed in segments with intact endothelium.
CONCLUSIONS:
In conclusion, the main mechanism responsible for the acute hypotensive effect of Visnagin is the vasorelaxant response induced by this drug in resistance arteries.
Biomed Pharmacother . 2019 Apr;112:108629.
Visnagin attenuates acute pancreatitis via Nrf2/NFκB pathway and abrogates associated multiple organ dysfunction[Pubmed: 30798137]
Abstract Acute pancreatitis (AP) is an exocrine dysfunction of the pancreas where oxidative stress and inflammatory cytokines play a key role in induction and progression of the disease. Studies have demonstrated that antioxidant phytochemicals have been effective in improving pancreatitis condition, but there are no clinically approved drugs till date. Our study aims to assess the preventive activity of Visnagin, a novel phytochemical isolated from Ammi visnaga against cerulein induced AP. Male Swiss albino mice were divided into six groups (n = 6, each group) comprising of normal control, cerulein control, seven day pre-treatment with Visnagin at three dose levels; Visnagin low dose (10 mg/kg), Visnagin mid dose (30 mg/kg), Visnagin high dose (60 mg/kg) and Visnagin control (60 mg/kg). AP was induced by six injections of cerulein (50 μg/kg, i.p.) on the 7th day and the animals were sacrificed after 6 h of last cerulein dose. Various markers of pancreatic function, oxidative stress and inflammation were assessed. Visnagin was found to be effective in reducing plasma amylase and lipase levels, reduced cerulein induced oxidative stress. Visnagin dose dependently decreased the expression of IL-1β, IL-6, TNF-α and IL-17. It attenuated the levels of nuclear p65-NFκB. Visnagin improved the antioxidant defence by improving Nrf2 expression and halted pancreatic inflammation by suppressing NFκB and nitrotyrosine expression in the acinar cells. Further, it attenuated the expression of markers of multiple organ dysfunction syndrome and reduced inflammatory cytokines in lungs and intestine. Cumulatively, these findings indicate that Visnagin has substantial potential to prevent cerulein induced AP. Keywords: Acute pancreatitis; Inflammation; NFκB; Nitrotyrosine; Nrf2; Visnagin.
Visnagin Description
Source: The herbs of Ammi visnaga.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
ChemFaces New Products and Compounds
Arisantetralone B

Catalog No: CFN95211
CAS No: 1161947-96-1
Price: $413/5mg
New compound 11

Catalog No: CFN95351
CAS No: N/A
Price: $318/10mg
Momordicine V

Catalog No: CFN95164
CAS No: 1012315-36-4
Price: $463/5mg
N-trans-caffeoyltyramine

Catalog No: CFN95265
CAS No: 103188-48-3
Price: $318/5mg
Formononetin-8-C-beta-D-apiofurano...

Catalog No: CFN95157
CAS No: 1147858-78-3
Price: $318/10mg
Peiioside B

Catalog No: CFN95336
CAS No: 1610618-91-1
Price: $318/5mg
Eriodictyol 7-O-glucuronide

Catalog No: CFN95290
CAS No: 125535-06-0
Price: $318/10mg
Clinopodic acid E

Catalog No: CFN95595
CAS No: 159736-38-6
Price: $318/5mg
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.344 mL 21.7202 mL 43.4405 mL 86.881 mL 108.6012 mL
5 mM 0.8688 mL 4.344 mL 8.6881 mL 17.3762 mL 21.7202 mL
10 mM 0.4344 mL 2.172 mL 4.344 mL 8.6881 mL 10.8601 mL
50 mM 0.0869 mL 0.4344 mL 0.8688 mL 1.7376 mL 2.172 mL
100 mM 0.0434 mL 0.2172 mL 0.4344 mL 0.8688 mL 1.086 mL
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
Protocol
Kinase Assay:
Arch Pharm Res. 2010 Nov;33(11):1843-50.
Anti-inflammatory effect of visnagin in lipopolysaccharide-stimulated BV-2 microglial cells.[Pubmed: 21116788]
Visnagin, which is found in Ammi visnaga, has biological activity as a vasodilator and reduces blood pressure by inhibiting calcium influx into the cell.
METHODS AND RESULTS:
The present study demonstrates the anti-inflammatory effect of Visnagin on lipopolysaccharide (LPS)-stimulated BV-2 microglial cells. When cells were treated with Visnagin prior to LPS stimulation, production of nitric oxide and expression of iNOS were attenuated in a dose-dependent manner. Visnagin also caused a significant decrease of mRNA expression and release of TNF-α, IL-1β and IFNγ. In addition, Visnagin reduced LPS-induced IL-6 and MCP-1 mRNA level. We further found that Visnagin dose-dependently inhibited LPS-induced AP-1 and NF-κB luciferase activities.
CONCLUSIONS:
Taken together, our results for the first time suggest that the anti-inflammatory effect of Visnagin might result from the inhibition of transcription factors, such as AP-1 and NF-κB.
Gen Pharmacol. 1999 Jan;32(1):71-4.
Effects of visnagin on cyclic nucleotide phosphodiesterases and their role in its inhibitory effects on vascular smooth muscle contraction.[Pubmed: 9888257]

METHODS AND RESULTS:
1. Visnagin relaxed aortae previously contracted by noradrenaline. This effect was unalterated by endothelium removal and potentiated, at high concentrations, by the previous incubation with sodium nitroprusside. 2. Visnagin weakly inhibited the hydrolytic activity of the cyclic nucleotide phosphodiesterase (PDE) isozymes (PDE5, PDE4, PDE3, cyclic GMP activated PDE2 and PDE1).
CONCLUSIONS:
3. The present results indicate an involvement of PDE inhibition in the relaxant effect of Visnagin at high concentration (>5x10(-5) M).
Cell Research:
Phytomedicine. 2010 Jul; 17(0): 653–658.
An aqueous extract of Ammi visnaga fruits and its constituents khellin and visnagin prevent cell damage caused by oxalate in renal epithelial cells。[Reference: WebLink]
Teas prepared from the fruits of Ammi visnaga L. (syn. “Khella”) have been traditionally used in Egypt as a remedy to treat kidney stones. It was the aim of our study to evaluate the effect of a Khella extract (KE) as well as the two major constituents khellin and Visnagin on renal epithelial injury using LLC-PK1 and Madin-Darby-canine kidney (MDCK) cells.
METHODS AND RESULTS:
Both cell lines provide suitable model systems to study cellular processes that are possibly involved in the development of a renal stone. LLC-PK1 and MDCK cell lines were exposed to 300 μM oxalate (Ox) or 133 μg/cm2 calcium oxalate monohydrate (COM) in presence or absence of 10, 50, 100 or 200 μg/mL KE. To evaluate cell damage, cell viability was assessed by determining the release of lactate dehydrogenase (LDH). KE (e.g. 100 μg/ml) significantly decreased LDH release from LLC-PK1 (Ox: 8.46± 0.76%; Ox + 100 μg/ml KE: 5.41± 0.94%, p<0.001) as well as MDCK cells (Ox: 30.9± 6.58%; Ox + 100 μg/ml KE: 17.5± 2.50%, p<0.001), which indicated a prevention of cell damage. Similar effects for KE were observed in both cell lines when COM crystals were added. In LLC-PK1 cells khellin and Visnagin both decreased the % LDH release significantly in cells that were pretreated with Ox or COM crystals. However, khellin and Visnagin exhibited different responses in MDCK cells. Whereas khellin slightly reduced the % LDH release after exposure of the cells to Ox and COM crystals, Visnagin significantly decreased % LDH release only after COM crystal exposure. Overall both compounds were more active in LLC-PK1 than in MDCK cells.
CONCLUSIONS:
In summary, exposure of renal epithelial cells to Ox or COM crystals was associated with a significant release of LDH indicating cell injury. Our data demonstrate that KE as well as khellin and Visnagin could prevent renal epithelial cell damage caused by Ox and COM and could therefore play a potential role in the prevention of stone formation associated with hyperoxaluria.
Animal Research:
Sci Transl Med. 2014 Dec 10;6(266):266ra170.
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.[Pubmed: 25504881]
Doxorubicin is a highly effective anticancer chemotherapy agent, but its use is limited by its cardiotoxicity.
METHODS AND RESULTS:
To develop a drug that prevents this toxicity, we established a doxorubicin-induced cardiomyopathy model in zebrafish that recapitulates the cardiomyocyte apoptosis and contractility decline observed in patients. Using this model, we screened 3000 compounds and found that Visnagin (VIS) and diphenylurea (DPU) rescue the cardiac performance and circulatory defects caused by doxorubicin in zebrafish. VIS and DPU reduced doxorubicin-induced apoptosis in cultured cardiomyocytes and in vivo in zebrafish and mouse hearts. VIS treatment improved cardiac contractility in doxorubicin-treated mice. Further, VIS and DPU did not reduce the chemotherapeutic efficacy of doxorubicin in several cultured tumor lines or in zebrafish and mouse xenograft models. Using affinity chromatography, we found that VIS binds to mitochondrial malate dehydrogenase (MDH2), a key enzyme in the tricarboxylic acid cycle. As with VIS, treatment with the MDH2 inhibitors mebendazole, thyroxine, and iodine prevented doxorubicin cardiotoxicity, as did treatment with malate itself, suggesting that modulation of MDH2 activity is responsible for VIS' cardioprotective effects.
CONCLUSIONS:
Thus, VIS and DPU are potent cardioprotective compounds, and MDH2 is a previously undescribed, druggable target for doxorubicin-induced cardiomyopathy.
(+)-Borneol

Catalog No: CFN70111
CAS No: 464-43-7
Price: $30/20mg
Dihydroevocarpine

Catalog No: CFN92786
CAS No: 15266-35-0
Price: $268/10mg
Notopterol

Catalog No: CFN98563
CAS No: 88206-46-6
Price: $80/20mg
Linarin

Catalog No: CFN98738
CAS No: 480-36-4
Price: $40/20mg
Isorhynchophylline

Catalog No: CFN96197
CAS No: 6859-01-4
Price: $138/20mg
3,4-Dihydroxybenzoic acid

Catalog No: CFN97568
CAS No: 99-50-3
Price: $30/20mg
Asimilobine

Catalog No: CFN96772
CAS No: 6871-21-2
Price: $ / mg
Dihydrophaseic acid

Catalog No: CFN98657
CAS No: 41756-77-8
Price: $ /
1,2,3,6-Tetragalloylglucose

Catalog No: CFN00447
CAS No: 79886-50-3
Price: $238/10mg
Alizarin

Catalog No: CFN92568
CAS No: 72-48-0
Price: $30/20mg
Tags: buy Visnagin | Visnagin supplier | purchase Visnagin | Visnagin cost | Visnagin manufacturer | order Visnagin | Visnagin distributor